Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Aliment Pharmacol Ther ; 42(7): 867-79, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-26314275

RESUMO

BACKGROUND: Crohn's disease recurs in the majority of patients after intestinal resection. AIM: To compare the relative efficacy of thiopurines and anti-TNF therapy in patients at high risk of disease recurrence. METHODS: As part of a larger study comparing post-operative management strategies, patients at high risk of recurrence (smoker, perforating disease, ≥2nd operation) were treated after resection of all macroscopic disease with 3 months metronidazole together with either azathioprine 2 mg/kg/day or mercaptopurine 1.5 mg/kg/day. Thiopurine-intolerant patients received adalimumab induction then 40 mg fortnightly. Patients underwent colonoscopy at 6 months with endoscopic recurrence assessed blind to treatment. RESULTS: A total of 101 patients [50% male; median (IQR) age 36 (25-46) years] were included. There were no differences in disease history between thiopurine- and adalimumab-treated patients. Fifteen patients withdrew prior to 6 months, five due to symptom recurrence (of whom four were colonoscoped). Endoscopic recurrence (Rutgeerts score i2-i4) occurred in 33 of 73 (45%) thiopurine vs. 6 of 28 (21%) adalimumab-treated patients [intention-to-treat (ITT); P = 0.028] or 24 of 62 (39%) vs. 3 of 24 (13%) respectively [per-protocol analysis (PPA); P = 0.020]. Complete mucosal endoscopic normality (Rutgeerts i0) occurred in 17/73 (23%) vs. 15/28 (54%) (ITT; P = 0.003) and in 27% vs. 63% (PPA; P = 0.002). The most advanced disease (Rutgeerts i3 and i4) occurred in 8% vs. 4% (thiopurine vs. adalimumab). CONCLUSIONS: In Crohn's disease patients at high risk of post-operative recurrence adalimumab is superior to thiopurines in preventing early disease recurrence.


Assuntos
Adalimumab/uso terapêutico , Azatioprina/administração & dosagem , Doença de Crohn/prevenção & controle , Doença de Crohn/cirurgia , Mercaptopurina/administração & dosagem , Metronidazol/administração & dosagem , Adulto , Idoso , Azatioprina/efeitos adversos , Colonoscopia/métodos , Doença de Crohn/diagnóstico , Quimioterapia Combinada , Feminino , Seguimentos , Humanos , Masculino , Mercaptopurina/efeitos adversos , Metronidazol/efeitos adversos , Pessoa de Meia-Idade , Período Pós-Operatório , Recidiva , Fatores de Risco , Resultado do Tratamento , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Fator de Necrose Tumoral alfa/imunologia
2.
Colorectal Dis ; 15(2): 187-97, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22757652

RESUMO

AIM: Eighty per cent of patients with Crohn's disease require surgery, of whom 70% will require a further operation. Recurrence occurs at the anastomosis. Although often recommended, the impact of postoperative colonoscopy and treatment adjustment is unknown. METHOD: Patients with a bowel resection over a 10-year period were reviewed and comparison made between those who did and did not have a postoperative colonoscopy within 1 year of surgery, and those who did or did not have a step-up in drug therapy. RESULTS: Of 222 patients operated on, 136 (65 men, mean age 33 years, mean disease duration 8 years, median follow-up 4 years) were studied. Of 70 patients with and 66 without postoperative colonoscopy, clinical recurrence occurred in 49% and 48% (NS) and further surgery in 9% and 5% (NS). Eighty-nine per cent of colonoscoped patients had a decision based on the colonoscopic findings: of these, 24% had a step-up of drug therapy [antibiotics (n =10), aminosalicylates (n=2), thiopurine (n=5), methotrexate (n=1)] and 76% had no step-up in drug therapy. In colonoscoped patients clinical recurrence occurred in 9 (60%) of 15 patients with, and 23 (49%) of 47 without step-up and surgical recurrence in 2 (13%) of 15 and 4 (9%) of 47 (NS). CONCLUSION: Clinical recurrence occurs in a majority of patients soon after surgery. In this cohort, there was no clinical benefit from colonoscopy or increased drug therapy within 1 year after operation. However, the response to the endoscopic findings was not standardized and immunosuppressive therapy was uncommon. Standardizing timing of colonoscopy and drug therapy, including more intense therapy, may improve outcome, although this remains to be proven.


Assuntos
Colo/cirurgia , Colonoscopia/métodos , Doença de Crohn/cirurgia , Íleo/cirurgia , Recidiva Local de Neoplasia/diagnóstico , Adolescente , Adulto , Anastomose Cirúrgica , Doença de Crohn/diagnóstico , Doença de Crohn/tratamento farmacológico , Procedimentos Cirúrgicos do Sistema Digestório/métodos , Feminino , Humanos , Imunossupressores/uso terapêutico , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Cuidados Pós-Operatórios/métodos , Complicações Pós-Operatórias/cirurgia , Complicações Pós-Operatórias/terapia , Resultado do Tratamento
3.
Intern Med J ; 40(11): 788-91, 2010 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-21155157

RESUMO

A young man with known steroid refractory terminal ileal Crohn's disease developed torrential gastrointestinal bleeding necessitating an emergency ileal resection. Serology was indicative of primary cytomegalovirus (CMV) infection and this was confirmed with histopathology of the resected ileum. We highlight the difficulty in clinical practice of distinguishing between CMV infection and CMV disease as well as the different investigations available to aid in the diagnosis of pathogenic CMV disease.


Assuntos
Doença de Crohn/tratamento farmacológico , Infecções por Citomegalovirus/diagnóstico , Hemorragia Gastrointestinal/diagnóstico , Ileíte/diagnóstico , Esteroides/uso terapêutico , Adulto , Doença de Crohn/complicações , Doença de Crohn/cirurgia , Infecções por Citomegalovirus/complicações , Infecções por Citomegalovirus/cirurgia , Hemorragia Gastrointestinal/complicações , Hemorragia Gastrointestinal/cirurgia , Humanos , Ileíte/complicações , Ileíte/cirurgia , Masculino
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...